ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for CNTA

Stock NameCentessa Pharmaceuticals PLC ADR
TickerCNTA(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS1523091007
LEI213800GIDAARDSKOI827

Show aggregate CNTA holdings

News associated with CNTA

Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated at Oppenheimer
Oppenheimer began coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Free Report) in a research report sent to investors on Friday morning. The firm issued an outperform rating and a $40.00 target price on the stock. CNTA has been the topic of several other research reports. Chardan Capital reaffirmed a “buy” rating and set a […] - 2025-09-01 03:02:48
Centessa Pharmaceuticals (NASDAQ:CNTA) Earns “Buy” Rating from Chardan Capital
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a report issued on Tuesday,Benzinga reports. They currently have a $30.00 price target on the stock. Chardan Capital’s price objective would suggest a potential upside of 75.03% from the stock’s current price. A number of […] - 2025-08-14 03:14:57
Analysts Set Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Price Target at $28.10
Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) have earned an average rating of “Buy” from the eleven analysts that are covering the company, Marketbeat.com reports. Eleven equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued a report on […] - 2025-08-13 03:04:43
XTX Topco Ltd Increases Position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)
XTX Topco Ltd raised its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) by 81.0% in the first quarter, Holdings Channel.com reports. The firm owned 41,057 shares of the company’s stock after purchasing an additional 18,377 shares during the period. XTX Topco Ltd’s holdings in Centessa Pharmaceuticals were worth $590,000 […] - 2025-08-06 05:20:57
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) CEO Sells $875,600.00 in Stock
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) CEO Saurabh Saha sold 55,000 shares of the stock in a transaction on Monday, July 21st. The shares were sold at an average price of $15.92, for a total value of $875,600.00. Following the completion of the sale, the chief executive officer owned 221,017 shares […] - 2025-07-23 05:50:50
Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated at Truist Financial
Investment analysts at Truist Financial initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat.com reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Truist Financial’s target price indicates a potential upside of 85.53% from […] - 2025-07-23 05:10:48
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Average Rating of “Buy” from Brokerages
Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) have received an average recommendation of “Buy” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated […] - 2025-07-16 02:49:05
Nxera Pharma To Receive $4.8 Mln Milestone As Centessa Advances ORX142 To Phase 1 Study
(RTTNews) - Nxera Pharma Co., Ltd. announced it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals under their research collaboration. The payments follow Centessa's initiation of clinical development for ORX142, its second novel orexin receptor 2 (OX - 2025-07-04 04:13:48
Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.8% Following Insider Selling
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) shares fell 3.8% during trading on Thursday following insider selling activity. The stock traded as low as $12.95 and last traded at $12.93. 65,287 shares were traded during mid-day trading, a decline of 91% from the average session volume of 726,424 shares. The stock had […] - 2025-06-27 02:17:08
Saurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Stock
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $12.63, for a total value of $694,650.00. Following the completion of the transaction, the chief executive officer now owns […] - 2025-06-23 05:25:00
We Did The Math TMSL Can Go To $38
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-10 08:53:34
Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stake Lowered by Two Sigma Investments LP
Two Sigma Investments LP reduced its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Free Report) by 63.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,900 shares of the company’s stock after selling 66,008 shares during the period. […] - 2025-06-09 04:56:44
Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $27.00 Average PT from Brokerages
Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has been given a consensus rating of “Buy” by the ten research firms that are currently covering the stock, Marketbeat reports. Ten research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock […] - 2025-05-30 03:06:54
Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated at Needham & Company LLC
Stock analysts at Needham & Company LLC assumed coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) in a note issued to investors on Wednesday, MarketBeat reports. The brokerage set a “buy” rating and a $35.00 price target on the stock. Needham & Company LLC’s price objective indicates a potential upside of 167.79% […] - 2025-05-30 02:21:02
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up After Insider Buying Activity
Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) gapped up before the market opened on Tuesday following insider buying activity. The stock had previously closed at $12.26, but opened at $12.74. Centessa Pharmaceuticals shares last traded at $12.97, with a volume of 107,299 shares trading hands. Specifically, Director Arjun Goyal acquired 417,646 shares of the […] - 2025-05-22 02:32:56
Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock Holdings Increased by Barclays PLC
Barclays PLC grew its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Free Report) by 1,414.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,302 shares of the company’s stock after buying an additional 4,952 shares during the period. […] - 2025-05-15 04:31:09
Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $27.71 Consensus PT from Analysts
Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have received a consensus rating of “Buy” from the eight analysts that are currently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in […] - 2025-05-05 02:34:53
Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $27.71 Average Price Target from Brokerages
Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have been given a consensus rating of “Buy” by the eight brokerages that are currently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a report on […] - 2025-04-10 03:07:13
Centessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Analysts at Piper Sandler
Stock analysts at Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $38.00 price target on the stock. Piper Sandler’s target price indicates a potential upside of 187.23% […] - 2025-04-02 03:12:49
Guggenheim Reaffirms Buy Rating for Centessa Pharmaceuticals (NASDAQ:CNTA)
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research report issued on Wednesday,Benzinga reports. They presently have a $28.00 price target on the stock. Guggenheim’s target price suggests a potential upside of 92.97% from the stock’s previous close. Several other brokerages have […] - 2025-03-28 05:02:42
Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $917,950.00 in Stock
Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $16.69, for a total transaction of $917,950.00. Following the transaction, the chief executive officer now owns 276,017 shares of the company’s […] - 2025-03-24 06:04:57
Analysts Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Target Price at $25.83
Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock […] - 2025-02-19 04:12:50

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) CNTA holdings

DateNumber of CNTA Shares HeldBase Market Value of CNTA SharesLocal Market Value of CNTA SharesChange in CNTA Shares HeldChange in CNTA Base ValueCurrent Price per CNTA Share HeldPrevious Price per CNTA Share Held
2025-12-24 (Wednesday)64,200USD 1,648,656CNTA holding increased by 26964USD 1,648,6560USD 26,964 USD 25.68 USD 25.26
2025-12-23 (Tuesday)64,200CNTA holding decreased by -1800USD 1,621,692CNTA holding decreased by -53388USD 1,621,692-1,800USD -53,388 USD 25.26 USD 25.38
2025-12-22 (Monday)66,000USD 1,675,080CNTA holding increased by 34980USD 1,675,0800USD 34,980 USD 25.38 USD 24.85
2025-12-19 (Friday)66,000CNTA holding decreased by -5306USD 1,640,100CNTA holding decreased by -131854USD 1,640,100-5,306USD -131,854 USD 24.85 USD 24.85
2025-12-18 (Thursday)71,306USD 1,771,954CNTA holding decreased by -9270USD 1,771,9540USD -9,270 USD 24.85 USD 24.98
2025-12-17 (Wednesday)71,306CNTA holding decreased by -815USD 1,781,224CNTA holding decreased by -73728USD 1,781,224-815USD -73,728 USD 24.98 USD 25.72
2025-12-16 (Tuesday)72,121CNTA holding decreased by -163USD 1,854,952CNTA holding decreased by -35275USD 1,854,952-163USD -35,275 USD 25.72 USD 26.15
2025-12-15 (Monday)72,284CNTA holding increased by 326USD 1,890,227CNTA holding decreased by -17380USD 1,890,227326USD -17,380 USD 26.15 USD 26.51
2025-12-12 (Friday)71,958USD 1,907,607CNTA holding decreased by -48211USD 1,907,6070USD -48,211 USD 26.51 USD 27.18
2025-12-11 (Thursday)71,958CNTA holding increased by 2189USD 1,955,818CNTA holding decreased by -107251USD 1,955,8182,189USD -107,251 USD 27.18 USD 29.57
2025-12-10 (Wednesday)69,769USD 2,063,069CNTA holding increased by 67676USD 2,063,0690USD 67,676 USD 29.57 USD 28.6
2025-12-09 (Tuesday)69,769USD 1,995,393CNTA holding decreased by -62793USD 1,995,3930USD -62,793 USD 28.6 USD 29.5
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of CNTA by Blackrock for IE00BYXG2H39

Show aggregate share trades of CNTA

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-12-23SELL-1,80025.58025.030 25.085USD -45,153 17.75 Loss of -13,199 on sale
2025-12-19SELL-5,30625.28024.170 24.281USD -128,835 17.69 Loss of -34,985 on sale
2025-12-17SELL-81525.97024.810 24.926USD -20,315 17.62 Loss of -5,952 on sale
2025-12-16SELL-16326.69525.530 25.647USD -4,180 17.59 Loss of -1,314 on sale
2025-12-15BUY32626.75525.950 26.031USD 8,486 17.55
2025-12-11BUY2,18928.59026.499 26.708USD 58,465 17.46
2025-12-04BUY3,16029.74028.520 28.642USD 90,509 17.19
2025-12-02BUY2,37029.14028.260 28.348USD 67,185 17.08
2025-11-28BUY15829.50028.980 29.032USD 4,587 16.97
2025-11-26BUY47429.99028.530 28.676USD 13,592 16.85
2025-11-26BUY47429.99028.530 28.676USD 13,592 16.85
2025-11-25BUY79029.89528.860 28.964USD 22,881 16.80
2025-11-24BUY15829.45028.000 28.145USD 4,447 16.74
2025-11-20SELL-63229.33027.480 27.665USD -17,484 16.63 Loss of -6,975 on sale
2025-11-19BUY15828.83027.513 27.645USD 4,368 16.57
2025-11-18BUY94829.00027.150 27.335USD 25,914 16.52
2025-11-17BUY31629.26027.210 27.415USD 8,663 16.46
2025-11-14BUY15827.72025.881 26.064USD 4,118 16.41
2025-11-12BUY15827.18022.000 22.518USD 3,558 16.31
2025-11-10BUY15823.08021.795 21.924USD 3,464 16.25
2025-11-06BUY15824.15022.100 22.305USD 3,524 16.18
2025-11-04BUY15824.16523.000 23.117USD 3,652 16.11
2025-10-30BUY79024.73023.450 23.578USD 18,627 15.98
2025-10-29BUY31623.98025.250 25.123USD 7,939 15.94
2025-10-22SELL-63223.28023.490 23.469USD -14,832 15.72 Loss of -4,900 on sale
2025-10-20BUY31622.79023.240 23.195USD 7,330 15.64
2025-10-17BUY78923.02023.340 23.308USD 18,390 15.60
2025-10-15BUY1,25622.57022.740 22.723USD 28,540 15.56
2025-10-03BUY1,10623.23023.600 23.563USD 26,061 15.48
2025-10-02BUY15823.05023.160 23.149USD 3,658 15.44
2025-09-30BUY31624.25024.570 24.538USD 7,754 15.35
2025-09-26BUY31623.26023.480 23.458USD 7,413 15.25
2025-09-25BUY31623.01023.890 23.802USD 7,521 15.20
2025-09-24SELL-1,98623.97024.130 24.114USD -47,890 15.15 Loss of -17,799 on sale
2025-09-18BUY16422.97023.090 23.078USD 3,785 15.11
2025-09-17BUY49521.85022.400 22.345USD 11,061 15.07
2025-08-20SELL-65617.28017.530 17.505USD -11,483 14.99 Loss of -1,650 on sale
2025-07-30BUY65616.56017.690 17.577USD 11,531 14.91
2025-07-17SELL-32815.96016.000 15.996USD -5,247 14.87 Loss of -371 on sale
2025-07-11SELL-1,31214.43014.730 14.700USD -19,286 14.86 Profit of 209 on sale
2025-07-07BUY49213.62014.135 14.084USD 6,929 14.88
2025-07-02BUY9,07513.74013.880 13.866USD 125,834 14.90
2025-06-20BUY2,57012.43013.020 12.961USD 33,310 14.92
2025-06-11BUY31412.49012.870 12.832USD 4,029 15.04
2025-06-10BUY31412.12012.415 12.385USD 3,889 15.07
2025-06-04SELL-15612.53013.440 13.349USD -2,082 15.16 Profit of 282 on sale
2025-04-23BUY15613.03013.500 13.453USD 2,099 15.82
2025-04-10SELL-1,24811.27011.780 11.729USD -14,638 16.21 Profit of 5,592 on sale
2025-04-08SELL-15610.71012.390 12.222USD -1,907 16.32 Profit of 640 on sale
2025-04-07SELL-15611.28011.860 11.802USD -1,841 16.38 Profit of 715 on sale
2025-04-04SELL-78011.68012.760 12.652USD -9,869 16.44 Profit of 2,953 on sale
2025-04-01BUY2,21313.23014.340 14.229USD 31,489 16.51
2025-03-31SELL-45314.38014.890 14.839USD -6,722 16.54 Profit of 769 on sale
2025-03-21BUY2,96915.75016.635 16.547USD 49,127 16.63
2025-03-14SELL-2,27217.14017.500 17.464USD -39,678 16.62 Loss of -1,912 on sale
2025-03-07SELL-28216.23017.290 17.184USD -4,846 16.63 Loss of -155 on sale
2025-03-04SELL-14216.33016.440 16.429USD -2,333 16.63 Profit of 29 on sale
2025-02-25BUY28415.75016.000 15.975USD 4,537 16.73
2025-02-19SELL-14115.91016.880 16.783USD -2,366 16.77 Loss of -2 on sale
2025-02-13BUY42017.62018.330 18.259USD 7,669 16.75
2025-02-12BUY14118.00018.140 18.126USD 2,556 16.72
2025-02-11BUY56417.26017.890 17.827USD 10,054 16.71
2024-12-30BUY4,98616.35016.725 16.688USD 83,204 16.56
2024-11-18SELL-1,83016.10016.157 16.151USD -29,557 15.73 Loss of -772 on sale
2024-11-08SELL-12216.50016.870 16.833USD -2,054 15.58 Loss of -152 on sale
2024-10-21SELL-12315.79016.245 16.200USD -1,993 0.00 Loss of -1,993 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of CNTA

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1996,1770334,78128.7%
2025-09-18426,5300753,19356.6%
2025-09-17188,60901,023,96118.4%
2025-09-1699,3650660,28415.0%
2025-09-15183,4320383,03847.9%
2025-09-12197,758217618,63332.0%
2025-09-11185,3700655,21828.3%
2025-09-10698,6311,1001,910,00836.6%
2025-09-09572,0931,8621,760,16832.5%
2025-09-08642,71802,271,08528.3%
2025-09-0583,80713214,45339.1%
2025-09-04117,4067,437513,07422.9%
2025-09-03437,62336,8581,631,66626.8%
2025-09-02168,5590321,07152.5%
2025-08-2999,8050265,70337.6%
2025-08-2849,0390136,22936.0%
2025-08-27123,6340442,71427.9%
2025-08-26278,0530572,48248.6%
2025-08-2553,0430132,37940.1%
2025-08-22130,8510443,77629.5%
2025-08-21205,0870526,85038.9%
2025-08-20125,9338,100284,05644.3%
2025-08-19186,8480411,71745.4%
2025-08-18122,6930228,81853.6%
2025-08-15201,3180604,26633.3%
2025-08-14184,41823,957484,62038.1%
2025-08-13168,5500660,96525.5%
2025-08-12140,3990559,81525.1%
2025-08-11137,4580298,82446.0%
2025-08-08118,2610245,07848.3%
2025-08-07164,3160378,79843.4%
2025-08-06164,0010547,57530.0%
2025-08-05190,3550947,01920.1%
2025-08-04209,9440979,06721.4%
2025-08-01166,3170263,60763.1%
2025-07-31389,319100626,95562.1%
2025-07-30758,48701,534,54849.4%
2025-07-2974,8070126,46559.2%
2025-07-2861,8620218,70828.3%
2025-07-2572,8592,404135,07053.9%
2025-07-2468,70618183,51137.4%
2025-07-23186,1120713,45426.1%
2025-07-2291,7280296,00531.0%
2025-07-21175,40522,136469,21537.4%
2025-07-18134,5690390,01434.5%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy